Effectiveness of Diquafosol Prophylactic Therapy to Prevent Dry Eye Disease for Cataract Surgery Patients in Indonesia
Status:
Recruiting
Trial end date:
2024-03-15
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to determine the effectiveness of preventive therapy with
diquafosol sodium 3% compared to sodium hyaluronate 0.1% to prevent dry eye disease in
patient who will undergo cataract surgery. The main questions it aims to answer are:
- The percentage reduction in subjective symptoms and signs of dry eye disease after
cataract surgery.
- The differences in the use of diquafosol sodium 3% and sodium hyaluronate 0.1% in
improving dry eye disease signs in patients objectively.
- The tear osmolarity and matix metalloproteinase-9 (MMP-9) after the treatment.
- The difference in visual quality improvement assessed from higher order aberrations
(HOA) and contrast sensitivity after administration of diquafosol sodium 3% compared to
sodium hyaluronate 0.1%.
Participants will receive diquafosol sodium 3% or sodium hyaluronate 0.1% for 4 weeks before
the cataract surgery and 21 days after the surgery, and will be:
- Interviewed regarding their identity, history of illness, and symptoms of dry eye
disease.
- Examined by researchers: eye condition, contrast sensitivity using the Pelli-Robson
diagram, keratograph, HOA, tear osmolarity, MMP-9, corneal sensitivity, tear break up
time (TBUT) , fluorescein break up pattern (FBUP).
This examination will be carried out 4 times: on the first day before the research series,
four weeks after giving therapy before cataract surgery, 21 days after cataract surgery, and
90 days after cataract surgery.